President Trump's April 2026 executive order to accelerate psychedelic drug development prompted the FDA to award priority review vouchers to three companies, reducing potential approval times from up ...

Executives from several psychedelic drug developers said they are pushing forward with conventional, large-scale clinical ...

COMPASS presents a “scalable framework” for other centers that want to improve AF care, but additional efforts are needed.

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus ...

Compass Pathways (NASDAQ:CMPS) is a biotech company focused on developing psychedelic treatments for mental health issues.

The FDA has awarded Compass Pathways a priority review voucher and rolling submission for its COMP360 psilocybin therapy for treatment-resistant depression, potentially cutting review time to one or ...

The FDA has issued National Priority Vouchers to three psychedelic medications. The National Priority Voucher program is a ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Trump's embrace of psychedelics and cannabis is shaking up the GOP’s relationship with mind-altering substances.

Webcast scheduled for Monday, April 27, 2026 at 8:00am ET.BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), ...

The FDA is awarding national priority vouchers to Compass Pathways and the Usona Institute as the Trump administration looks ...

The FDA on Friday moved to speed up the development of new treatments using some psychedelic ‌drugs for serious mental ...